Literature DB >> 23389962

The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy.

Jasmohan S Bajaj1, Leroy R Thacker, Douglas M Heuman, Michael Fuchs, Richard K Sterling, Arun J Sanyal, Puneet Puri, Mohammad S Siddiqui, Richard T Stravitz, Iliana Bouneva, Velimir Luketic, Nicole Noble, Melanie B White, Pamela Monteith, Ariel Unser, James B Wade.   

Abstract

UNLABELLED: Minimal hepatic encephalopathy (MHE) detection is difficult because of the unavailability of short screening tools. Therefore, MHE patients can remain undiagnosed and untreated. The aim of this study was to use a Stroop smartphone application (app) (EncephalApp_Stroop) to screen for MHE. The app and standard psychometric tests (SPTs; 2 of 4 abnormal is MHE, gold standard), psychometric hepatic encephalopathy score (PHES), and inhibitory control tests (ICTs) were administered to patients with cirrhosis (with or without previous overt hepatic encephalopathy; OHE) and age-matched controls from two centers; a subset underwent retesting. A separate validation cohort was also recruited. Stroop has an "off" state with neutral stimuli and an "on" state with incongruent stimuli. Outcomes included time to complete five correct runs as well as number of trials needed in on (Ontime) and off (Offtime) states. Stroop results were compared between controls and patients with cirrhosis with or without OHE and those with or without MHE (using SPTs, ICTs, and PHES). Receiver operating characteristic analysis was performed to diagnose MHE in patients with cirrhosis with or without previous OHE. One hundred and twenty-five patients with cirrhosis (43 previous OHE) and 134 controls were included in the original cohort. App times were correlated with Model for End-Stage Liver Disease (Offtime: r = 0.57; Ontime: r = 0.61; P < 0.0001) and were worst in previous OHE patients, compared to the rest and controls. Stroop performance was also significantly impaired in those with MHE, compared to those without MHE, according to SPTs, ICTs, and PHES (all P < 0.0001). A cutoff of >274.9 seconds (Ontime plus Offtime) had an area under the curve of 0.89 in all patients and 0.84 in patients without previous OHE for MHE diagnosis using SPT as the gold standard. The validation cohort showed 78% sensitivity and 90% specificity with the >274.9-seconds Ontime plus Offtime cutoff. App result patterns were similar between the centers. Test-retest reliability in controls and those without previous OHE was good; a learning effect on Ontime in patients with cirrhosis without previous OHE was noted.
CONCLUSION: The Stroop smartphone app is a short, valid, and reliable tool for screening of MHE.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23389962      PMCID: PMC3657327          DOI: 10.1002/hep.26309

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

Review 1.  Neuropsychological characterization of hepatic encephalopathy.

Authors:  K Weissenborn; J C Ennen; H Schomerus; N Rückert; H Hecker
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

Review 2.  Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations.

Authors:  María Ortiz; Carlos Jacas; Juan Córdoba
Journal:  J Hepatol       Date:  2004-12-28       Impact factor: 25.083

3.  Attention dysfunction in cirrhotic patients: an inquiry on the role of executive control, attention orienting and focusing.

Authors:  Piero Amodio; Sami Schiff; Franco Del Piccolo; Daniela Mapelli; Angelo Gatta; Carlo Umiltà
Journal:  Metab Brain Dis       Date:  2005-06       Impact factor: 3.584

4.  Testing for minimal hepatic encephalopathy in the United States: An AASLD survey.

Authors:  Jasmohan Singh Bajaj; Ashkan Etemadian; Muhammad Hafeezullah; Kia Saeian
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 5.  The attention system of the human brain.

Authors:  M I Posner; S E Petersen
Journal:  Annu Rev Neurosci       Date:  1990       Impact factor: 12.449

6.  Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation.

Authors:  James H Sorrell; Bryan J Zolnikov; Ashish Sharma; Izumi Jinnai
Journal:  Psychiatry Clin Neurosci       Date:  2006-04       Impact factor: 5.188

7.  Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.

Authors:  Srinivasa Prasad; Radha K Dhiman; Ajay Duseja; Yogesh K Chawla; Arpita Sharma; Ritesh Agarwal
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 8.  Attention, memory, and cognitive function in hepatic encephalopathy.

Authors:  Karin Weissenborn; Kathrin Giewekemeyer; Susanne Heidenreich; Martin Bokemeyer; Georg Berding; Björn Ahl
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

9.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; James B Wade; Arun J Sanyal; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Richard K Sterling; Velimir Luketic; Iliana Bouneva; Richard T Stravitz; Puneet Puri; Kenneth A Kraft; Hochong Gilles; Douglas M Heuman
Journal:  J Hepatol       Date:  2012-08-11       Impact factor: 25.083

View more
  72 in total

Review 1.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

Review 2.  Minimal hepatic encephalopathy.

Authors:  Laura M Stinton; Saumya Jayakumar
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

Review 3.  Brain edema: a valid endpoint for measuring hepatic encephalopathy?

Authors:  Chantal Bémeur; Cristina Cudalbu; Gitte Dam; Alexander S Thrane; Arthur J L Cooper; Christopher F Rose
Journal:  Metab Brain Dis       Date:  2016-06-07       Impact factor: 3.584

Review 4.  Diagnosis of minimal hepatic encephalopathy.

Authors:  Karin Weissenborn
Journal:  J Clin Exp Hepatol       Date:  2014-07-31

Review 5.  Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes.

Authors:  Mary J Thomson; Anna S Lok; Elliot B Tapper
Journal:  Liver Int       Date:  2018-06-19       Impact factor: 5.828

6.  Disrupted topological organization of brain structural network associated with prior overt hepatic encephalopathy in cirrhotic patients.

Authors:  Hua-Jun Chen; Hai-Bin Shi; Long-Feng Jiang; Lan Li; Rong Chen
Journal:  Eur Radiol       Date:  2017-06-30       Impact factor: 5.315

7.  Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Richard K Sterling; Arun J Sanyal; Muhammad Siddiqui; Scott Matherly; Velimir Luketic; R Todd Stravitz; Michael Fuchs; Leroy R Thacker; HoChong Gilles; Melanie B White; Ariel Unser; James Hovermale; Edith Gavis; Nicole A Noble; James B Wade
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-17       Impact factor: 11.382

8.  Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.

Authors:  Meghan NeSmith; Joseph Ahn; Steven L Flamm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

Review 9.  Useful tests for hepatic encephalopathy in clinical practice.

Authors:  Eiman Nabi; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2014-01

10.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.